Table 1.
Baseline demographics and disease characteristics
| Characteristic | n | All | n | Moderate: IGA = 3 | n | Severe: IGA = 4 |
|---|---|---|---|---|---|---|
| Male, n (%) | 300 | 182 (60.7) | 220 | 135 (61.4) | 80 | 47 (58.8) |
| Female, n (%) | 300 | 118 (39.3) | 220 | 85 (38.6) | 80 | 33 (41.3) |
| Age (years; median [range]) | 300 | 34.0 (20–58) | 220 | 35.0 (20–58) | 80 | 33.0 (20–57) |
| Height (cm; median [range]) | 299 | 165.30 (145.0–185.3) | 219 | 165.50 (145.0–185.3) | 80 | 165.15 (145.0–180.0) |
| Weight (kg; median [range]) | 299 | 60.50 (36.0–111.3) | 219 | 62.00 (36.0–111.3) | 80 | 59.50 (43.0–102.8) |
| BMI (kg/m2; median [range]) | 299 | 21.91 (15.7–41.4) | 219 | 22.03 (15.9–41.4) | 80 | 21.75 (15.7–39.3) |
| Age of onset (years; median [range]) | 300 | 3.0 (0–52) | 220 | 4.0 (0–52) | 80 | 3.0 (0–48) |
| AD disease duration (years; median [range]) | 300 | 25.53 (0.6–55.5) | 220 | 25.56 (0.6–55.5) | 80 | 25.32 (1.1–52.3) |
| No. of visits for AD treatments in the past 1 year (times; median [range]) | 298 | 8.0 (0–120) | 220 | 8.0 (0–50) | 78 | 6.5 (0–120) |
| IGA score (median [range]) | 300 | 3.0 (3–4) | 220 | 3.0 (3–3) | 80 | 4.0 (4–4) |
| EASI total score (median [range]) | 300 | 21.700 (3.40–72.00) | 220 | 18.000 (3.40–53.40) | 80 | 40.750 (17.00–72.00) |
| BSA (%; median [range]) | 300 | 46.25 (10.0–100.0) | 220 | 38.70 (10.0–99.0) | 80 | 78.50 (24.0–100.0) |
| DLQI total score (median [range]) | 300 | 6.0 (0–30) | 220 | 6.0 (0–30) | 80 | 12.5 (2–29) |
| EQ‐5D utility score (median [range]) | 299 | 0.8228 (0.102–1.000) | 219 | 0.8709 (0.121–1.000) | 80 | 0.7184 (0.102–1.000) |
| EQ‐5D VAS (median [range]) | 297 | 70.0 (0–100) | 217 | 70.0 (0–100) | 80 | 60.0 (0–100) |
| POEM total score (median [range]) | 300 | 16.0 (2–28) | 220 | 14.5 (2–28) | 80 | 21.5 (7–28) |
| Pruritus score by NRS (median [range]) | 297 | 7.0 (0–10) | 217 | 6.0 (0–10) | 80 | 8.0 (3–10) |
AD, atopic dermatitis; BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EQ‐5D, EuroQOL group health questionnaire with five dimensions; IGA, Investigator's Global Assessment; NRS, numerical rating scale; POEM, Patient‐Oriented Eczema Measure.